Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: William Rastetter, Ajay Bansal

Premium

Regulus has appointed William Rastetter to its board of directors. Rastetter is currently chairman of the board of Illumina, Fate Therapeutics, Neurocrine Biosciences, and Receptos. He holds a PhD and MA in chemistry from Harvard University.


Onconova has appointed Ajay Bansal chief financial officer. Bansal most recently served as chief financial officer for Complete Genomics. He has also served as chief financial officer and executive vice president of corporate and business development for Lexicon Therapeutics and Tercica. He has also worked in strategy and marketing for Novartis Pharmaceuticals and held positions at consulting firms such as McKinsey & Company. He holds master's degrees in management and operations research from Northwestern University.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.